Kyrtsonis Maria-Christina, Siakantaris Marina P, Kalpadakis Christina, Dimopoulou Maria N, Vassilakopoulos Theodoros P, Kontopidou Flora N, Antoniou Christina, Korkolopoulou Penelope, Panayiotidis Panayiotis, Pangalis Gerassimos A
First Department of Internal Medicine and Department of Haematology, National and Kapodistrian University of Athens, School of Medicine, Laikon General Hospital, Athens, Greece.
Eur J Haematol. 2006 Oct;77(4):300-3. doi: 10.1111/j.1600-0609.2006.00720.x. Epub 2006 Jul 19.
Primary cutaneous marginal zone lymphoma (PCMZL) is an indolent disease. Treatment options include excision, local irradiation, interferon-alpha or chemotherapy. We present two patients with PCMZL and multiple skin lesions successfully treated with intralesional administration of the anti-CD20 monoclonal antibody rituximab. The first presented with four red skin lesions and the second with two. Biopsy of the largest lesion revealed marginal zone B-cell lymphoma in both patients. There was no evidence of systemic involvement in either patient. Both patients were treated with intralesional rituximab for 18 consecutive weeks. Skin lesions gradually regressed. Apart from mild local pain during the injection, no other adverse effects were observed. In conclusion, rituximab can be safely administered intralesionally in patients with PCMZL and can produce disease remission.
原发性皮肤边缘区淋巴瘤（PCMZL）是一种惰性疾病。治疗选择包括手术切除、局部放疗、α干扰素或化疗。我们报告了两名患有PCMZL且有多处皮肤病变的患者，通过病灶内注射抗CD20单克隆抗体利妥昔单抗成功治愈。第一名患者有4处红色皮肤病变，第二名患者有2处。对两名患者最大的病变进行活检均显示为边缘区B细胞淋巴瘤。两名患者均无全身受累的证据。两名患者均连续18周接受病灶内注射利妥昔单抗治疗。皮肤病变逐渐消退。除注射期间有轻微局部疼痛外，未观察到其他不良反应。总之，利妥昔单抗可安全地用于PCMZL患者的病灶内注射，并可使疾病缓解。
